|
Match
|
Document |
Document Title |
|
|
EP1978029A2 |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7432342 |
Kinase anchor protein muteins, peptides thereof and related documents
A-kinase anchor protein (AKAPs) muteins, peptides thereof, and nucleic acids encoding the peptides are provided herein. Also provided are transgenic animals, cells comprising transgenes and various...
|
|
|
7432331 |
Hydrolytically stable maleimide-terminated polymers
The present invention is directed to hydrolytically stabilized maleimide-functionalized water soluble polymers and to methods for making and utilizing such polymers and their precursors.
|
|
|
7432330 |
Hydrolytically stable maleimide-terminated polymers
The present invention is directed to hydrolytically stabilized maleimide-functionalized water soluble polymers and to methods for making and utilizing such polymers and their precursors.
|
|
|
EP1975181A1 |
Use of vascular endothelial cell growth factor antagonists
The present invention provides vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that inhibit the mitogenic,...
|
|
|
EP0784093B1 |
Osteoprotegerin
|
|
|
EP1970386A2 |
Hybrid immunoglobulins
Novel peptides are provided, together with methods for making and using them, and nucleic acids encoding them. These peptides are useful as cell surface adhesion molecules and ligands, and are...
|
|
|
7425620 |
FcγRIIB-specific antibodies and methods of use thereof
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind...
|
|
|
7425619 |
FcγRIIB specific antibodies and methods of use thereof
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind...
|
|
|
EP1967587A1 |
APO-3 Ligand
A tumor necrosis factor and lymphotoxin homolog having apoptotic activity, identified as Apo-3 Ligand, is provided. Nucleic acid molecules encoding Apo-3 ligand, chimeric molecules and antibodies...
|
|
|
EP1967586A1 |
84P2A9: A prostate and testis specific protein highly expressed in prostate cancer
A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple...
|
|
|
7423014 |
Insulin conjugates for treating diabetes mellitus
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin polypeptide-oligomer conjugate of formula V
to the patient...
|
|
|
7419600 |
Method for purifying a branched water-soluble polymer
Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure
wherein Z is a moiety that can be activated for attachment to biologically active molecules...
|
|
|
EP1961760A2 |
Peptides and compounds that bind to a thrombopoietin receptor
Peptides and peptide mimetics of the sequence I E G P T L R Q W L A A R A, that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for...
|
|
|
7416858 |
Pharmaceutical compositions of glycoconjugates
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying...
|
|
|
EP1959014A2 |
Antibodies against insulin-like growth factor I receptor and uses thereof
An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-11 to IGF-IR which is characterized in that said antibody is a) is of IgGI isotype, b) shows a ratio of IC 50 values of...
|
|
|
EP1958965A2 |
Agonist antibodies to a musk receptor, and their therapeutic uses
Agonist antibody, fragment or variant that binds to a MuSK receptor, compositions and medical uses.
|
|
|
7414105 |
Peptides that bind to the erythropoietin receptor
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat...
|
|
|
7413738 |
Releasable polymeric conjugates based on biodegradable linkers
Activated polymeric bicine derivatives such as,
as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.
|
|
|
EP1956030A1 |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7411050 |
Monoclonal blocking antibody to human RANKL
Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
|
|
|
EP1953173A1 |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7408047 |
Fibroblast growth factor-like polypeptides
The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies...
|
|
|
7407932 |
Methods for glucagon suppression using modified exendins
Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for...
|
|
|
7407475 |
Modified annexin proteins, and methods and compositions for using them
A modified annexin protein, preferably annexin V, is used to prevent thrombosis without increasing hemorrhage. Annexin binds to phosphatidylserine on the outer surface of cell membranes, thereby...
|
|
|
EP1950300A2 |
Antibody variants with higher binding affinity compared to parent antibodies
Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which...
|
|
|
7405198 |
Glycopegylated erythropoietin
The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the...
|
|
|
EP1947182A1 |
Fibroblast growth factor-23 molecules and uses thereof
The present invention provides Fibroblast Growth Factor-23 (FGF-23) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host...
|
|
|
7402730 |
Knockout animals manifesting hyperlipidemia
Genetically engineered cells and animals are described that incorporate a mutated GHP1 allele. Animals that are homozygous for the mutated GHP1 allele are useful for the production of monoclonal...
|
|
|
EP1944317A2 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7399613 |
Sialic acid nucleotide sugars
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying...
|
|
|
7399489 |
Exendin analog formulations
Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.
|
|
|
EP1411075B1 |
Method for preparing polymer conjugates
|
|
|
EP1927659A1 |
Wisp polypeptides and therapeutical applications thereof
The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or degenerative cartilagenous disorders, including arthritis, comprising...
|
|
|
7381702 |
Methods of treating diabetes mellitus
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the...
|
|
|
EP1923400A1 |
Compositions and methods for the treatment of systemic lupus erythematosis
The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
|
|
|
7374917 |
Mutant 2.5-diketo-L-gluconic acid reductases
Described herein are novel nucleic acids, proteins and methods that can be used to provide new catalysts with desirable traits for industrial processes. In particular, novel reductases isolated...
|
|
|
7371834 |
Apoptosis-inducing factor
The present invention related generally novel mammalian apoptosis-inducing factors, polynucleotides encoding such factors and methods related thereto.
|
|
|
EP1918304A1 |
Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II)
The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing...
|
|
|
EP1915999A1 |
N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof.
The present invention provides a chemically modified human Growth Hormone (hGH) prepared by attaching a polyethylene glycol butyraldehyde moiety to the N-terminal phenylalanine of the protein. The...
|
|
|
7364736 |
Antibodies to OPGL
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are...
|
|
|
EP1914303A1 |
Thermus eggertssonii DNA polymerases
This invention relates to a thermophilic polymerase wherein the polymerase has an in vitro primer extension rate that is > 35 bases/second and faster relative to the primer extension rate of a...
|
|
|
7361341 |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
|
|
|
7351855 |
Chemically defined non-polymeric valency platform molecules and conjugates thereof
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
|
|
|
7351787 |
Process for the preparation of activated polyethylene glycols
A process for preparing activated polyethylene glycols is disclosed. In some embodiments, the process includes reacting a molten polyethylene glycol with an activator. In other embodiments, the...
|
|
|
7348312 |
Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.
|
|
|
7348148 |
Nucleic acid derivatives
A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality...
|
|
|
7348003 |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of...
|
|
|
7345150 |
Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions...
|
|
|
EP1897947A2 |
IL-17 homologous polypeptides and therapeutic uses thereof
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein a re vectors and host cells comprising those nucleic acid...
|